Search
Search Results
-
The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory drivers
Glioblastoma (GBM) is characterized by extensive cellular and genetic heterogeneity. Its initial presentation as primary disease (pGBM) has been...
-
A phase I clinical trial of sonodynamic therapy combined with temozolomide in the treatment of recurrent glioblastoma
PurposeThe prognosis of recurrent glioblastoma (rGBM) is poor, and there is currently no effective treatment strategy. Sonodynamic therapy (SDT) is a...
-
Global post‑marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011–2022
BackgroundTumor Treating Fields (TTFields) are alternating electric fields that disrupt cancer cell processes. TTFields therapy is approved for...
-
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma
IntroductionGlioblastoma (GBM) is the most common central nervous system malignancy in adults. Despite decades of developments in surgical...
-
Dose-dependent efficacy of bevacizumab in recurrent glioblastoma
BackgroundBevacizumab (BEV), at a standard dose of 10 mg/kg every 2 weeks is associated with prolonged progression-free survival (PFS) but no...
-
Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers
BackgroundThe optimal management strategy for recurrent glioblastoma (rGBM) remains uncertain, and the impact of re-irradiation (Re-RT) on overall...
-
Tumor Treating Fields (TTFields) therapy vs physicians’ choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19)
PurposeTumor Treating Fields (TTFields) therapy, a noninvasive, anti-mitotic treatment modality, is approved for recurrent glioblastoma (rGBM) and...
-
Cell-free plasma microRNAs that identify patients with glioblastoma
Glioblastoma (GBM) is still one of the most commonly diagnosed advanced stage primary brain tumors. Current treatments for patients with primary GBM...
-
Efficacy and safety of tumor-treating fields in recurrent glioblastoma: a systematic review and meta-analysis
BackgroundTumor-treating fields (TTF) is a novel cancer treatment that uses alternating electric fields to interfere with tumor cell mitosis. It has...
-
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors
BackgroundPreclinical studies have demonstrated that VT1021, a first-in-class therapeutic agent, inhibits tumor growth via stimulation of...
-
ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449
PurposeGliomagenesis and resistance of glioblastoma (GBM) are believed to be mediated by glioma stem cells (GSC). Evidence suggests that SHH...
-
Laser interstitial thermal therapy for recurrent glioblastomas: a systematic review and meta-analysis
We aim to investigate the efficacy and safety of laser interstitial thermal therapy (LITT) in treating recurrent glioblastomas (rGBMs). A...
-
Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma
IntroductionRecurrent glioblastoma (rGBM) prognosis is dismal. In the absence of effective adjuvant treatments for rGBM, re-resections remain...
-
PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma
IntroductionOptimal treatment for recurrent glioblastoma isocitrate dehydrogenase 1 and 2 wild-type (rGBM IDH-WT) is not standardized, resulting in...
-
Genomic alterations predictive of response to radiosurgery in recurrent IDH-WT glioblastoma
IntroductionDespite aggressive treatment, glioblastoma invariably recurs. The optimal treatment for recurrent glioblastoma (rGBM) is not well...
-
A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives
High-grade gliomas (HGGs) constitute the most common malignant primary brain tumor with a poor prognosis despite the standard multimodal therapy. In...
-
Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review
Glioblastoma (GBM) is a fatal brain tumour that is traditionally diagnosed based on histological features. Recent molecular profiling studies have...
-
High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient
BackgroundGlioblastomas (GBMs) in patients harboring somatic or germinal mutations of mismatch-repair (MMR) genes exhibit a hypermutable phenotype....
-
Clinical advances in oncolytic virus therapy for malignant glioma: a systematic review
PurposeIn the past decade, there has been little progress in the treatment of malignant glioma. Recently, oncolytic virus has made great progress in...
-
Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity
PurposeThis review compares reirradiation (reRT), systemic therapy and combination therapy (reRT & systemic therapy) with regards to overall survival...
